Hemorif DS 1000

Indications

Our medication is suitable for addressing the following conditions:

• Acute episodes of hemorrhoids.
• Chronic hemorrhoidal conditions.
• Chronic venous insufficiency in the lower limbs, characterized by symptoms such as leg heaviness, pain, and nocturnal cramps.

Ingredients

Each film-coated tablet contains:

• 450 mg of Diosmin micronized BP.
• 50 mg of Hesperidin micronized INN.

Each DS film-coated tablet contains:

• 900 mg of Diosmin micronized BP.
• 100 mg of Hesperidin micronized USP.

Pharmacological Action

Diosmin and Hesperidin act as phlebotonic agents and vascular protectors. They enhance venous tone by prolonging the effects of noradrenaline on vein walls. Consequently, they reduce venous capacitance, distensibility, and emptying time.

These compounds also safeguard the microcirculation by countering damaging processes, inflammation, and promoting lymphatic drainage.

Dosage

For Diosmin 450 mg & Hesperidin 50 mg:

• Acute hemorrhoidal attacks: Take 3 tablets twice daily for the initial 4 days, followed by 2 tablets twice daily for 3 days, then adjust to 1 tablet twice daily for maintenance.
• Chronic hemorrhoids: Take 1 tablet twice daily.
• Chronic venous insufficiency: Initially, take 1 tablet twice daily for seven days, with the possibility of adjusting duration based on severity.

For Diosmin 900 mg & Hesperidin 100 mg:

• Acute Hemorrhoid: Take 1 tablet thrice daily for the first 4 days, followed by 1 tablet twice daily for 3 days, then 1 tablet once daily for maintenance.
• Relapse of Internal Hemorrhoid & Chronic Hemorrhoid: Take 1 tablet once daily for 3 months.
• Chronic venous insufficiency: Take 1 tablet once daily for 2-6 months.
• Leg Wounds: Take 1 tablet once daily for 2 months.

Administration

Take tablets with meals.

Interactions

No evidence of drug interactions reported in clinical trials.

Contraindications

Seek medical consultation for diagnosis and management of chronic venous insufficiency. Avoid if allergic to any ingredient.

Side Effects

Reported cases include mild gastric and neurovegetative disorders, which typically do not necessitate discontinuation.

Pregnancy & Lactation

No teratogenic effects observed in animal studies. Caution advised during breastfeeding due to lack of data.

Precautions & Warnings

If symptoms persist beyond 15 days, consult a physician. Use with caution in patients with a history of cancer.

Therapeutic Class

Phlebotonic & Vascular protecting preparation.

Storage

Store below 30°C, away from light and moisture. Keep out of reach of children.